Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R. Gomez, George R. Blumenschein, Mike Hernández et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Medical Oncology +7

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Andrew Weickhardt, Benjamin Scheier, Joseph Burke et al. · Journal of Thoracic Oncology · 2012 · 677 citations · Full text

Medicine, Oncology, Pharmacology +15

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Helena A. Yu, Camelia S. Sima, James Huang et al. · Journal of Thoracic Oncology · 2013 · 342 citations · Full text

Medicine, Oncology, Pharmacology +14